{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T20:33:09Z","timestamp":1770150789417,"version":"3.49.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials Advances"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.bioadv.2022.213208","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T09:39:09Z","timestamp":1669282749000},"page":"213208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Affilin-based retargeting of adenoviral vectors to the epidermal growth factor receptor"],"prefix":"10.1016","volume":"144","author":[{"given":"Frederik","family":"Wienen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Nilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Allmendinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Graumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Fiedler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Bosse-Doenecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Kochanek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lea","family":"Krutzke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioadv.2022.213208_bb0005","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41419-019-1769-9","article-title":"Clinical update on head and neck cancer: molecular biology and ongoing challenges","volume":"10","author":"Alsahafi","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioadv.2022.213208_bb0010","first-page":"371","article-title":"Virus combinations and chemotherapy for the treatment of human cancers","volume":"10","author":"Kumar","year":"2008","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.bioadv.2022.213208_bb0015","first-page":"4968","article-title":"Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer","volume":"62","author":"Freytag","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioadv.2022.213208_bb0020","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1089\/104303403321467199","article-title":"Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points","volume":"14","author":"Sauthoff","year":"2003","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bioadv.2022.213208_bb0025","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1182\/blood-2006-04-008532","article-title":"Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes","volume":"108","author":"Parker","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bioadv.2022.213208_bb0030","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2008.01.016","article-title":"Adenovirus serotype 5 hexon mediates liver gene transfer","volume":"132","author":"Waddington","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.bioadv.2022.213208_bb0035","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1099\/0022-1317-81-11-2605","article-title":"Blood clearance rates of adenovirus type 5 in mice","volume":"81","author":"Alemany","year":"2000","journal-title":"J Gen Virol"},{"key":"10.1016\/j.bioadv.2022.213208_bb0040","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ymthe.2005.08.007","article-title":"Rapid kupffer cell death after intravenous injection of adenovirus vectors","volume":"13","author":"Manickan","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bioadv.2022.213208_bb0045","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1525-0016(02)00017-5","article-title":"Selective depletion or blockade of Kupffer cells leads to enhanced and prolonged hepatic transgene expression using high-capacity adenoviral vectors","volume":"7","author":"Schiedner","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bioadv.2022.213208_bb0050","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1089\/104303403322542275","article-title":"A hemodynamic response to intravenous adenovirus vector particles is caused by systemic kupffer cell-mediated activation of endothelial cells","volume":"14","author":"Schiedner","year":"2003","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bioadv.2022.213208_bb0055","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nm.3107","article-title":"Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement","volume":"19","author":"Xu","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioadv.2022.213208_bb0060","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","article-title":"International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials","volume":"28","author":"Mast","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.bioadv.2022.213208_bb0065","doi-asserted-by":"crossref","first-page":"11705","DOI":"10.1128\/JVI.01320-08","article-title":"Clearance of adenovirus by kupffer cells is mediated by scavenger receptors, natural antibodies, and complement","volume":"82","author":"Xu","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.bioadv.2022.213208_bb0070","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1128\/JVI.79.12.7478-7491.2005","article-title":"Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity","volume":"79","author":"Shayakhmetov","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.bioadv.2022.213208_bb0075","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1182\/blood-2008-09-178459","article-title":"Human erythrocytes bind and inactivate type 5 adenovirus by presenting coxsackie virus-adenovirus receptor and complement receptor 1","volume":"113","author":"Carlisle","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bioadv.2022.213208_bb0080","first-page":"2629","article-title":"Reduced expression of coxsackievirus and adenovirus receptor (CAR) in tumor tissue compared to normal epithelium in head and neck squamous cell carcinoma patients","volume":"22","author":"Jee","year":"2002","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bioadv.2022.213208_bb0085","first-page":"1057","article-title":"Coxsackie adenovirus receptor expression in carcinomas of the head and neck","volume":"32","author":"Wunder","year":"2012","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bioadv.2022.213208_bb0090","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1200\/JCO.2005.04.8306","article-title":"Epidermal growth factor receptor biology in head and neck cancer","volume":"24","author":"Kalyankrishna","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioadv.2022.213208_bb0095","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.12688\/f1000research.9025.1","article-title":"EGF receptor ligands: recent advances","volume":"5","author":"Singh","year":"2016","journal-title":"F1000Res"},{"key":"10.1016\/j.bioadv.2022.213208_bb0100","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1021\/bi00379a035","article-title":"Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor","volume":"26","author":"Yarden","year":"1987","journal-title":"Biochemistry"},{"key":"10.1016\/j.bioadv.2022.213208_bb0105","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioadv.2022.213208_bb0110","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.3389\/fonc.2020.01249","article-title":"The latest battles between EGFR monoclonal antibodies and resistant tumor cells","volume":"10","author":"Cai","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioadv.2022.213208_bb0115","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11523-015-0358-9","article-title":"Gefitinib: a review of its use in adults with advanced non-small cell lung cancer","volume":"10","author":"Dhillon","year":"2015","journal-title":"Target. Oncol."},{"key":"10.1016\/j.bioadv.2022.213208_bb0120","doi-asserted-by":"crossref","first-page":"120082","DOI":"10.1016\/j.ijpharm.2020.120082","article-title":"EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles","volume":"592","author":"Santos","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bioadv.2022.213208_bb0125","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.3390\/v2091844","article-title":"Increasing the efficacy of oncolytic adenovirus vectors","volume":"2","author":"Toth","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.bioadv.2022.213208_bb0130","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archotol.125.8.856","article-title":"Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma","volume":"125","author":"Blackwell","year":"1999","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.bioadv.2022.213208_bb0135","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/sj.cgt.7700198","article-title":"Targeting of adenoviral vectors through a bispecific single-chain antibody","volume":"7","author":"Haisma","year":"2000","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.bioadv.2022.213208_bb0140","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1128\/JVI.76.6.2753-2762.2002","article-title":"Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished","volume":"76","author":"van Beusechem","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.bioadv.2022.213208_bb0145","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1038\/sj.gt.3302103","article-title":"Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors","volume":"10","author":"van Beusechem","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.bioadv.2022.213208_bb0150","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.virol.2006.11.011","article-title":"A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor","volume":"361","author":"Carette","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.bioadv.2022.213208_bb0155","doi-asserted-by":"crossref","first-page":"6875","DOI":"10.1128\/JVI.74.15.6875-6884.2000","article-title":"Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells","volume":"74","author":"Dmitriev","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.bioadv.2022.213208_bb0160","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/sj.gt.3300511","article-title":"The \u2018adenobody\u2019 approach to viral targeting: specific and enhanced adenoviral gene delivery","volume":"4","author":"Watkins","year":"1997","journal-title":"Gene Ther."},{"key":"10.1016\/j.bioadv.2022.213208_bb0165","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41467-017-02707-6","article-title":"Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control","volume":"9","author":"Schmid","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioadv.2022.213208_bb0170","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1089\/hum.2009.190","article-title":"Targeting adenoviruses with factor x-single-chain antibody fusion proteins","volume":"21","author":"Chen","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bioadv.2022.213208_bb0175","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1089\/hum.2015.015","article-title":"Incorporation of peptides targeting EGFR and FGFR1 into the adenoviral fiber knob domain and their evaluation as targeted cancer therapies","volume":"26","author":"Uusi-Kerttula","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bioadv.2022.213208_bb0180","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymthe.2005.03.006","article-title":"Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors","volume":"12","author":"Kreppel","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bioadv.2022.213208_bb0185","doi-asserted-by":"crossref","first-page":"8493","DOI":"10.1074\/jbc.M113.519884","article-title":"Novel ubiquitin-derived high affinity binding proteins with tumor targeting properties","volume":"289","author":"Lorey","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioadv.2022.213208_bb0190","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1089\/104303400750001417","article-title":"Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production","volume":"11","author":"Schiedner","year":"2000","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bioadv.2022.213208_bb0195","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jconrel.2016.06.022","article-title":"Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: preventing vector clearance and preserving infectivity","volume":"235","author":"Krutzke","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioadv.2022.213208_bb0200","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1089\/hum.2020.045","article-title":"Chorioallantoic membrane tumor model for evaluating oncolytic viruses","volume":"31","author":"Krutzke","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bioadv.2022.213208_bb0205","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1128\/jvi.70.11.7498-7509.1996","article-title":"Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy","volume":"70","author":"Mittereder","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.bioadv.2022.213208_bb0210","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/gt.2011.87","article-title":"Coagulation factor X mediates adenovirus type 5 liver gene transfer in non-human primates (Microcebus murinus)","volume":"19","author":"Alba","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.bioadv.2022.213208_bb0215","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/73528","article-title":"Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis","volume":"24","author":"Chen","year":"2000","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bioadv.2022.213208_bb0220","doi-asserted-by":"crossref","first-page":"H65","DOI":"10.1152\/ajpheart.00866.2008","article-title":"Reduced EGFR causes abnormal valvular differentiation leading to calcific aortic stenosis and left ventricular hypertrophy in C57BL\/6J but not 129S1\/SvImJ mice","volume":"297","author":"Barrick","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.bioadv.2022.213208_bb0225","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1073\/pnas.0537588100","article-title":"Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function","volume":"100","author":"Iwamoto","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioadv.2022.213208_bb0230","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1161\/HYPERTENSIONAHA.112.196543","article-title":"Loss of epidermal growth factor receptor in vascular smooth muscle cells and cardiomyocytes causes arterial hypotension and cardiac hypertrophy","volume":"61","author":"Schreier","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.bioadv.2022.213208_bb0235","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.bbamcr.2016.03.017","article-title":"Substance-specific importance of EGFR for vascular smooth muscle cells motility in primary culture","volume":"1863","author":"Schreier","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bioadv.2022.213208_bb0240","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/ATVBAHA.111.223537","article-title":"Consequences of epidermal growth factor receptor (ErbB1) loss for vascular smooth muscle cells from mice with targeted deletion of ErbB1","volume":"31","author":"Schreier","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bioadv.2022.213208_bb0245","series-title":"The Role of Vascular Smooth Muscle Cells in the Physiology and Pathophysiology of Blood Vessels","author":"Bacakova","year":"2018"},{"key":"10.1016\/j.bioadv.2022.213208_bb0250","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0304-4165(85)90055-8","article-title":"Binding of epidermal growth factor from man, rat and mouse to the human epidermal growth factor receptor","volume":"843","author":"Nex\u00f8","year":"1985","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bioadv.2022.213208_bb0255","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1038\/onc.2016.509","article-title":"A loop of cancer-stroma-cancer interaction promotes peritoneal metastasis of ovarian cancer via TNF\u03b1-TGF\u03b1-EGFR","volume":"36","author":"Lau","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.bioadv.2022.213208_bb0260","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3390\/v13061136","article-title":"Transduction enhancers enable efficient human adenovirus type 5-mediated gene transfer into human multipotent mesenchymal stromal cells","volume":"13","author":"Nilson","year":"2021","journal-title":"Viruses"}],"container-title":["Biomaterials Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277295082200485X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277295082200485X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T13:44:19Z","timestamp":1757425459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S277295082200485X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":52,"alternative-id":["S277295082200485X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioadv.2022.213208","relation":{},"ISSN":["2772-9508"],"issn-type":[{"value":"2772-9508","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Affilin-based retargeting of adenoviral vectors to the epidermal growth factor receptor","name":"articletitle","label":"Article Title"},{"value":"Biomaterials Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioadv.2022.213208","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"213208"}}